Activated seven lupus anticoagulant (ASLA) assay
Screening tests commonly employ dilute phospholipid to accentuate the in vitro anticoagulant effect of LA, which if present, will prolong the clotting time. Screening tests can be prolonged for reasons other than LA, (i.e. factor deficiencies, anticoagulant therapy), so all elevated screening tests receive follow-up analyses to help define the nature of any abnormality. The confirm test generally involves performing the screening test in an identical fashion except that the phospholipid concentration is markedly increased. This has the effect of partially or completely overwhelming the LA and thus leads to a shorter clotting time than the screening test, thereby evidencing phospholipid dependence. Clotting times are converted to ratios to mitigate for issues of analytical variability. Correction of the screen ratio by the confirm ratio by ≥10% is considered consistent with the presence of a LA, providing that other causes of elevated clotting times are excluded. Diagnostic specificity is improved by performing the screen and confirmatory tests on 1:1 mixtures of test and normal plasma to evidence inhibition and reduce interferences, although the inevitable dilution effect can compromise this aspect of analysis.
Antibody heterogeneity and reagent variability necessitate use of at least two assays, of different analytical principle, to achieve acceptable detection rates. First-line assays are dilute Russell's viper venom time (dRVVT) and LA-responsive APTT yet a small proportion of LA will not react in either of these tests. One of the supplementary tests employed in our laboratories is the activated seven lupus anticoagulant (ASLA) assay, an 'extrinsic pathway' -based assay developed in these laboratories which utilises recombinant FVIIa to activate FX in vitro. Activation of FX leads to assembly of the prothrombinase complex, thrombin generation and clot formation. ASLA testing involves application of the screen, confirm amd mixing test medley and is reported with a full interpretation of the results. ASLA is not performed routinely and should be requested as an additional test.
Criteria antibodies for diagnosis of APS are lupus anticoagulant, anticardiolipin antibodies and/or β2 glycoprotein I antibodies. Persistence of one or more of these antibodies in the presence of appropriate clinical manifestations secures diagnosis of APS, although association and recurrence are higher in patients with multiple-positivity.
ASLA screen 0.90 – 1.11
ASLA confirm 0.92 – 1.08
ASLA mixing test screen 0.88 – 1.08
ASLA mixing test confirm 0.88 – 1.08
500µL x 2 aliquot
Internal requests: please refer to EPR label
The sample should be analysed or manipulated & stored in the laboratory within 4 hours of venepuncture. Please ensure sample tubes are filled exactly to the fill-line as underfilling creates a dilution error and leads to inaccurate results.
North Wing - 4th and 5th Floors
Westminster Bridge Road
London SE1 7EH
Laboratory opening times
Southwark Wing - 4th Floor
Great Maze Pond
London SE1 9RT
Outside core hours, contact Duty Haemostasis Biomedical Scientist
Last updated: 08/03/2017